Deborah Schrag

Deborah Schrag

Auto-generated profile, based on publicly available information

Deborah Schrag

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
IBIno de Bruijn
Ino de Bruijn
RKRitika Kundra
Ritika Kundra
BMBrooke Mastrogiacomo
Brooke Mastrogiacomo
TTThinh Ngoc. Tran
Thinh Ngoc. Tran
LSLuke Sikina
Luke Sikina
NSNikolaus Schultz
Nikolaus Schultz
International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international cancer registry collecting data from 19 cancer centers, makes data from >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional real-world longitudinal clinical data, including treatment and outcome data, are being collected by the AACR Project GENIE Biopharma Collaborative using the PRISSMM data curation model. Several thousand of these cases are now also available in cBioPortal. We have significantly enhanced the functionalities of cBioPortal to support the visualization and analysis of this rich clinico-genomic linked dataset, as well as datasets generated by other centers and consortia. Examples of these enhancements include (i) visualization of the longitudinal clinical and genomic data at the patient level, including timelines for diagnoses, treatments, and outcomes; (ii) the ability to select samples based on treatment status, facilitating a comparison of molecular and clinical attributes between samples before and after a specific treatment; and (iii) survival analysis estimates based on individual treatment regimens received. Together, these features provide cBioPortal users with a toolkit to interactively investigate complex clinico-genomic data to generate hypotheses and make discoveries about the impact of specific genomic variants on prognosis and therapeutic sensitivities in cancer. Significance: Enhanced cBioPortal features allow clinicians and researchers to effectively investigate longitudinal clinico-genomic data from patients with cancer, which will improve exploration of data from the AACR Project GENIE Biopharma Collaborative and similar datasets.

27 July 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
DSDeborah Schrag
Deborah Schrag
QSQian Shi
Qian Shi
MWMartin R. Weiser
Martin R. Weiser
MGMarc J. Gollub
Marc J. Gollub
LSLeonard B. Saltz
Leonard B. Saltz
HMHarvey J. Mamon
Harvey J. Mamon
Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) can be used in lieu of chemoradiotherapy is uncertain. We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX (with chemoradiotherapy given only if the primary tumor decreased in size by <20% or if FOLFOX was discontinued because of side effects) as compared with chemoradiotherapy. Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate. The primary end point was disease-free survival. Noninferiority would be claimed if the upper limit of the two-sided 90.2% confidence interval of the hazard ratio for disease recurrence or death did not exceed 1.29. Secondary end points included overall survival, local recurrence (in a time-to-event analysis), complete pathological resection, complete response, and toxic effects. From June 2012 through December 2018, a total of 1194 patients underwent randomization and 1128 started treatment; among those who started treatment, 585 were in the FOLFOX group and 543 in the chemoradiotherapy group. At a median follow-up of 58 months, FOLFOX was noninferior to chemoradiotherapy for disease-free survival (hazard ratio for disease recurrence or death, 0.92; 90.2% confidence interval [CI], 0.74 to 1.14; P = 0.005 for noninferiority). Five-year disease-free survival was 80.8% (95% CI, 77.9 to 83.7) in the FOLFOX group and 78.6% (95% CI, 75.4 to 81.8) in the chemoradiotherapy group. The groups were similar with respect to overall survival (hazard ratio for death, 1.04; 95% CI, 0.74 to 1.44) and local recurrence (hazard ratio, 1.18; 95% CI, 0.44 to 3.16). In the FOLFOX group, 53 patients (9.1%) received preoperative chemoradiotherapy and 8 (1.4%) received postoperative chemoradiotherapy. In patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival. (Funded by the National Cancer Institute; PROSPECT ClinicalTrials.gov number, NCT01515787.).

5 October 2023 in The Lancet
Verified
Journal Article
Closed access
DSDeb Schrag
Deb Schrag
TBTomasz M Beer
Tomasz M Beer
CMCharles H McDonnell
Charles H McDonnell
LNLincoln Nadauld
Lincoln Nadauld
CDChristina A Dilaveri
Christina A Dilaveri
EKEric A Klein
Eric A Klein

20 December 2000 in JAMA
Verified
Journal Article
Open access
PDF file
DSDeborah Schrag
Deborah Schrag
LCLaura D. Cramer
Laura D. Cramer
PBPeter B. Bach
Peter B. Bach
ACAlfred M. Cohen
Alfred M. Cohen
JWJoan L. Warren
Joan L. Warren
CBColin B. Begg
Colin B. Begg
The complexity of health care processes makes identification and measurement of the critical components of high-quality care especially challenging.1 Because hospital procedure volume is relatively easy to measure and is assumed to be a proxy for experience, it has long been examined as a predictor of clinical outcomes, and a volume-outcome relationship has been observed for a wide variety of surgeries.2-13 Concentration of surgeries in high-volume centers has been considered a strategy to improve the quality of care,2,14-16 and in select instances, policies to achieve this goal have been implemented.17

1 November 2002 in Annals of Surgery
Verified
Journal Article
Closed access
DSDeborah Schrag
Deborah Schrag
KPKatherine S. DrPH Panageas
Katherine S. DrPH Panageas
ERElyn Ma Riedel
Elyn Ma Riedel
LCLaura D. ScM Cramer
Laura D. ScM Cramer
JGJose G. Guillem
Jose G. Guillem
CBColin B. Begg
Colin B. Begg
Objective To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer. Summary Background Data Although a “volume–outcome” relationship exists for several major cancer operations, the impact of procedure volume on outcomes following rectal cancer surgery remains uncertain, and it has not been determined whether hospital or surgeon volume is a more important predictor of outcomes. Methods A retrospective population-based cohort study utilizing the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database identified 2,815 rectal cancer patients aged 65 and older who had surgery for a primary tumor diagnosed in 1992–1996 in a SEER area. Hospital- and surgeon-specific procedure volume was ascertained based on the number of claims submitted over the 5-year study period. Outcome measures were mortality at 30 days and 2 years, overall survival, and the rate of abdominoperineal resections. Age, sex, race, comorbid illness, cancer stage, and socioeconomic status were used to adjust for differences in case mix. Results Neither hospital- nor surgeon-specific procedure volume was significantly associated with 30-day postoperative mortality or rates of rectal sphincter-sparing operations. Although an association between hospital volume and mortality at 2 years was evident, this finding was no longer significant once surgeon-specific volume was controlled for. In contrast, surgeon-specific volume was associated with 2-year mortality and remained an important predictor even after adjustment for hospital volume. Surgeon volume was also better than hospital procedure volume at predicting long-term survival. Conclusions Surgeon-specific experience as measured by procedure volume can have a significant impact on survival for patients with rectal cancer.

17 August 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
DSDeborah Schrag
Deborah Schrag
KCKi Young Chung
Ki Young Chung
CFCarlos Flombaum
Carlos Flombaum
LSLeonard Saltz
Leonard Saltz
We report that patients treated with cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), occasionally develop a magnesium wasting syndrome with inappropriate urinary excretion. We first observed this phenomenon in a 34-year-old male patient with metastatic colorectal cancer who developed profound fatigue and symptomatic hypocalcemia and hypomagnesemia while on cetuximab plus irinotecan therapy. Other medications with the potential to cause magnesium wasting had not been administered. Intravenous magnesium supplementation was required for the duration of cetuximab therapy, but electrolyte abnormalities resolved after discontinuation of treatment. This case prompted review of serum chemistry reports for a consecutive case series of 154 colorectal cancer patients treated with cetuximab. Thirty-four patients (22%) had at least one serum magnesium measurement during cetuximab treatment, and six had grade 3 (<0.9 mg/dL) and two had grade 4 (<0.7 mg/dL) hypomagnesemia. Because EGFR is strongly expressed in the kidney, particularly in the ascending limb of the loop of Henle where 70% of filtered magnesium is reabsorbed, EGFR blockade may interfere with magnesium transport. Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary.